NCT06890299

A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions

An Open-label, Randomized, Fed, Single-dose, 2-sequence, 2-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

The purpose of this clinical study is to evaluate the pharmacokinetics and safety between single oral administration of BR3006 and co-administration of BR3006A, BR3006B and BR3006C in healthy adult volunteers under fed conditions

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	BR3006	One tablet administered alone
DRUG	BR3006A	One tablet administered alone
DRUG	BR3006B	One tablet administered alone
DRUG	BR3006C	One tablet administered alone

Timeline

• Start date: 2024-12-05
• Primary completion: 2025-01-12
• Completion: 2025-01-12
• First posted: 2025-03-24
• Last updated: 2025-03-24

Locations

1 site across 1 country: South Korea